| Business

Become a contributor

Bookmark Econotimes

| Business

Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible

Washington Post Publisher Will Lewis Steps Down After Layoffs

Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge

Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal

Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports

TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans

Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil

DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins

American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns

Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape

FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns

Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks

Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning

Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies

Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances

Samsung Electronics Shares Jump on HBM4 Mass Production Report

SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates

©Econometrics LLC . All Rights Reserved.

CoLucid Pharmaceuticals to Present Corporate Overview at the Cowen & Company 36th Annual Health Care Conference

Thursday, March 3, 2016 1:00 PM UTC

CAMBRIDGE, Mass., March 03, 2016 -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today announced that Thomas Mathers, Chief Executive Officer, will present a corporate overview at the Cowen &Company 36^th Annual Health Care Conference, taking place March 7-9 at the Boston Marriott Copley Place.

*Cowen & Company 36^th Annual Health Care Conference -- CoLucid Presentation Details*
Date:	Tuesday, March 8
Time:	8:40am – 9:10am Eastern Time
Location:	Boston Marriott Copley Place, Berkeley Room, 3^rd Floor
Webcast:	http://wsw.com/webcast/cowen30/clcd

About CoLucid Pharmaceuticals, Inc.
CoLucid is developing oral lasmiditan for the acute treatment of migraine in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.

CONTACT
Thomas Mathers                         
Chief Executive Officer             
CoLucid Pharmaceuticals, Inc.  
(781) 365-2596                           

Hans Vitzthum
Managing Director
LifeSci Advisors, LLC.
(212) 915-2568

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Market Data

Nicaragua Ends Visa-Free Entry for Cubans, Disrupting Key Migration Route to the U.S.

Samsung Electronics Shares Jump on HBM4 Mass Production Report

Trump Congratulates Japan’s First Female Prime Minister Sanae Takaichi After Historic Election Victory

Ghislaine Maxwell to Invoke Fifth Amendment at House Oversight Committee Deposition

Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances

Japan’s Prime Minister Sanae Takaichi Secures Historic Election Win, Shaking Markets and Regional Politics

Trump Administration Appeals Court Order to Release Hudson Tunnel Project Funding

Israel Approves West Bank Measures Expanding Settler Land Access

Anutin’s Bhumjaithai Party Wins Thai Election, Signals Shift Toward Political Stability

EconoTimes

Disclaimer: EconoTimes provides references and links to selected blogs and other sources of economic and market information as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the blogs or other sources of information. Clients and prospects are advised to carefully consider the opinions and analysis offered in the blogs or other information sources in the context of the client or prospect's individual analysis and decision making. None of the blogs or other sources of information is to be considered as constituting a track record. Past performance is no guarantee of future results and EconoTimes specifically advises clients and prospects to carefully review all claims and representations made by advisors, bloggers, money managers and system vendors before investing any funds or opening an account with any Brokerage. Any news, opinions, research, data, or other information contained within this website is provided as general market commentary and does not constitute investment or trading advice. EconoTimes expressly disclaims any liability for any lost principal or profits without limitation which may arise directly or indirectly from the use of or reliance on such information. As with all such advisory services, past results are never a guarantee of future results.

CoLucid Pharmaceuticals to Present Corporate Overview at the Cowen & Company 36th Annual Health Care Conference

Editor's Picks

Welcome to EconoTimes